Michael Callaghan, Michael Bell, Stephen Kaufman, Douglas Bryant, Michael Cicirelli, Ronald Dudek, Todd Schwoerer, Richard Walter, Herbert Heyneker, Oya Yavuz, Kuno Sommer | GenomeWeb
Ciphergen Biosystems said that its shareholders had elected Michael Callaghan, Kenneth Conway, and James Rathmann as Class I directors for three-year terms.

Thermo Fisher Scientific has named Michael Bell and Stephen Kaufman to its board. Bell is one of the managing directors of Monitor Clipper Partners, and Kaufman is a senior lecturer of business administration at the Harvard Business School.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.